FDA approves Qlosi for treatment of presbyopia in adults

The U.S. Food and Drug Administration has approved Qlosi (pilocarpine hydrochloride ophthalmic solution; Orasis Pharmaceuticals) 0.4% for the treatment of presbyopia in adults. QLOSI is expected to be commercially available in the U.S. in the first half of 2024.

Qlosi is a prescription eye drop that can be used daily, or as needed, up to twice per day. QLOSI demonstrated efficacy 20 minutes after administration and can last up to 8 hours, as measured on day 15, to improve near vision without impacting distance or night vision. QLOSI is a preservative-free formulation of pilocarpine, an established eye care therapeutic, designed to achieve an optimal balance between efficacy, safety, and comfort.

Read the full press release here.